167 related articles for article (PubMed ID: 37642751)
21. Low bone mineral density is associated with breast cancer in postmenopausal women: a case-control study.
Ferreira Poloni P; Vespoli HL; Almeida-Filho BS; Bueloni-Dias F; Nahas-Neto J; Nahas EAP
Climacteric; 2017 Oct; 20(5):491-497. PubMed ID: 28569124
[TBL] [Abstract][Full Text] [Related]
22. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
[TBL] [Abstract][Full Text] [Related]
23. Association between Bone Mineral Density and Bone Turnover Markers in Breast Cancer Patients and Bone-Only Metastasis.
Kundaktepe BP; Sozer V; Kundaktepe FO; Durmus S; Papila C; Uzun H; Simsek G; Gelisgen R
Medicina (Kaunas); 2021 Aug; 57(9):. PubMed ID: 34577803
[No Abstract] [Full Text] [Related]
24. Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal women with breast cancer.
Hong AR; Kim JH; Lee KH; Kim TY; Im SA; Kim TY; Moon HG; Han WS; Noh DY; Kim SW; Shin CS
Osteoporos Int; 2017 Apr; 28(4):1413-1422. PubMed ID: 28083668
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of zoledronic acid for prevention of bone loss in early-stage breast cancer patients receiving adjuvant therapy: A meta-analysis of 13 randomized controlled trials.
Mei M; Xiang Z; Yang J; Xiang R
Curr Probl Cancer; 2020 Apr; 44(2):100507. PubMed ID: 31732237
[TBL] [Abstract][Full Text] [Related]
26. Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients.
Saarto T; Blomqvist C; Välimäki M; Mäkelä P; Sarna S; Elomaa I
J Clin Oncol; 1997 Apr; 15(4):1341-7. PubMed ID: 9193325
[TBL] [Abstract][Full Text] [Related]
27. Study on the Effect of Bushen Zhuanggu Tablet Combined with Conventional Regimen on Bone Mineral Density Improvement, Functional Recovery and Fracture Risk Prevention in Patients with Postmenopausal Osteoporosis.
Chen T; Li G; Xu Y
Comput Math Methods Med; 2023; 2023():4846392. PubMed ID: 37455682
[TBL] [Abstract][Full Text] [Related]
28. Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study.
Ueno T; Masuda N; Sato N; Ohtani S; Yamamura J; Matsunami N; Kashiwaba M; Takano T; Takahashi M; Kaneko K; Ohno S; Morita S; Toi M
Jpn J Clin Oncol; 2020 Jan; 50(1):3-11. PubMed ID: 31821506
[TBL] [Abstract][Full Text] [Related]
29. Discordance in lumbar bone mineral density measurements by quantitative computed tomography and dual-energy X-ray absorptiometry in postmenopausal women: a prospective comparative study.
Lin W; He C; Xie F; Chen T; Zheng G; Yin H; Chen H; Wang Z
Spine J; 2023 Feb; 23(2):295-304. PubMed ID: 36343911
[TBL] [Abstract][Full Text] [Related]
30. The effect of weight training on bone mineral density and bone turnover in postmenopausal breast cancer survivors with bone loss: a 24-month randomized controlled trial.
Waltman NL; Twiss JJ; Ott CD; Gross GJ; Lindsey AM; Moore TE; Berg K; Kupzyk K
Osteoporos Int; 2010 Aug; 21(8):1361-9. PubMed ID: 19802506
[TBL] [Abstract][Full Text] [Related]
31. Prevention of bone loss by zoledronic acid in premenopausal women undergoing adjuvant chemotherapy persist up to one year following discontinuing treatment.
Hershman DL; McMahon DJ; Crew KD; Shao T; Cremers S; Brafman L; Awad D; Shane E
J Clin Endocrinol Metab; 2010 Feb; 95(2):559-66. PubMed ID: 20022990
[TBL] [Abstract][Full Text] [Related]
32. Effects of zoledronic acid versus placebo on bone mineral density and bone texture analysis assessed by the trabecular bone score in premenopausal women with breast cancer treatment-induced bone loss: results of the ProBONE II substudy.
Kalder M; Kyvernitakis I; Albert US; Baier-Ebert M; Hadji P
Osteoporos Int; 2015 Jan; 26(1):353-60. PubMed ID: 25381047
[TBL] [Abstract][Full Text] [Related]
33. Bone mineral density in premenopausal women treated for node-positive early breast cancer with 2 years of goserelin or 6 months of cyclophosphamide, methotrexate and 5-fluorouracil (CMF).
Fogelman I; Blake GM; Blamey R; Palmer M; Sauerbrei W; Schumacher M; Serin D; Stewart A; Wilpshaar W
Osteoporos Int; 2003 Dec; 14(12):1001-6. PubMed ID: 14530912
[TBL] [Abstract][Full Text] [Related]
34. Negative impact on bone homeostasis in postmenopausal women with non-metastatic breast cancer during cytotoxic chemotherapy.
Nisha Y; Dubashi B; Bobby Z; Sahoo JP; Kayal S; Ananthakrishnan R; Reddy VB; L C; Ganesan P
J Bone Miner Metab; 2023 Sep; 41(5):682-692. PubMed ID: 37410202
[TBL] [Abstract][Full Text] [Related]
35. Assessment of ovarian failure and osteoporosis in premenopausal breast cancer survivors.
McCune JS; Games DM; Espirito JL
J Oncol Pharm Pract; 2005 Jun; 11(2):37-43. PubMed ID: 16460603
[TBL] [Abstract][Full Text] [Related]
36. Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer.
Oostra DR; Lustberg MB; Reinbolt RE; Pan X; Wesolowski R; Shapiro CL
Mol Cell Endocrinol; 2015 Feb; 402():51-6. PubMed ID: 25575458
[TBL] [Abstract][Full Text] [Related]
37. Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment.
Vehmanen L; Saarto T; Elomaa I; Mäkelä P; Välimäki M; Blomqvist C
Eur J Cancer; 2001 Dec; 37(18):2373-8. PubMed ID: 11720830
[TBL] [Abstract][Full Text] [Related]
38. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
39. The first multicenter and randomized clinical trial of herbal Fufang for treatment of postmenopausal osteoporosis.
Zhu HM; Qin L; Garnero P; Genant HK; Zhang G; Dai K; Yao X; Gu G; Hao Y; Li Z; Zhao Y; Li W; Yang J; Zhao X; Shi D; Fuerst T; Lu Y; Li H; Zhang X; Li C; Zhao J; Wu Q; Zhao SJ
Osteoporos Int; 2012 Apr; 23(4):1317-27. PubMed ID: 21505910
[TBL] [Abstract][Full Text] [Related]
40. Uncoupled bone remodeling is characteristic of bone damage in premenopausal women with new-onset systemic lupus erythematosus.
Zhu L; Zhang J; Wang J; Lv X; Pu D; Wang Y; Men Q; He L
Lupus; 2021 Jun; 30(7):1116-1123. PubMed ID: 33832361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
